Lenacapavir: A Game Changer in HIV Prevention?
The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at preventing HIV transmission. Gilead Sciences, the producer, ensures availability in 120 countries. Concerns arise over its limited access, especially in Latin America, despite its efficacy in preventing HIV.
- Country:
- United Kingdom
The European Medicines Agency has given the green light to authorize lenacapavir, a bi-annual injectable drug, as a significant step in HIV prevention. The drug, marketed as Yeytuo by Gilead Sciences, has shown impressive results in curbing the virus's transmission.
Once the European Commission approves, the authorization will cover all EU member states and select non-EU countries. Tests revealed nearly 100% effectiveness in halting HIV transmission, prompting UNAIDS's Winnie Byanyima to label it a potential game-changer.
Despite its promising results, access concerns persist. Gilead plans to distribute affordable versions in 120 countries with high HIV prevalence, excluding most of Latin America. This decision raises alarms about missing key opportunities to end global outbreaks.
(With inputs from agencies.)
Google News